Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib, a Dual SYK/JAK Inhibitor

Posted: Thursday, December 19, 2019

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II findings that showed good tolerability and clinical activity in peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Across subtypes of both disease states, researchers observed complete and durable responses. Correlative studies are aimed at identifying predictors of response and resistance.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.